Investigational Epcoritamab (Duobody® Cd3xcd20) Combination Therapy Demonstrates High Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory (R/R) Follicular Lymphoma (FL)
Investigational Epcoritamab (Duobody® Cd3xcd20) Combination Therapy Demonstrates High Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory (R/R) Follicular Lymphoma (FL) . (MENAFN - GlobeNewsWire - Nasdaq)   Media Release    COPENHAGEN, Denmark; December 7, 2024      Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967504/Investigational-Epcoritamab-Duobody-Cd3xcd20-Combination-Therapy-Demonstrates-High-Response-Rates-In-Clinical-Trial-Of-Patients-With-Relapsed-Or-Refractory-RR-Follicular-Lymphoma-FL
2024-12-07
rss
(MENAFN - GlobeNewsWire - Nasdaq)   Media Release    COPENHAGEN, Denmark; December 7, 2024      Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent ...
Investigational Epcoritamab (Duobody® Cd3xcd20) Combination Therapy Demonstrates High Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory (R/R) Follicular Lymphoma (FL)